Skip to main content
Premium Trial:

Request an Annual Quote

BioFire Diagnostics Gets $25M Investment

NEW YORK (GenomeWeb News) – BioFire Diagnostics today announced that it has received a $25 million investment from Athyrium Opportunities Fund.

The Salt Lake City-based firm, which recently changed its name from Idaho Technology, will use the funds to accelerate commercialization of its FilmArray diagnostic platform and panels that run on the platform. The firm already holds US Food and Drug Administration clearance and the CE IVD Mark for its FilmArray Respiratory Panel, which simultaneously tests 17 viral targets and three bacterial targets in roughly one hour.

BioFire is currently developing panels for blood culture ID, gastrointestinal disorders, and meningitis.

"This investment strengthens our already solid capital position and the company's ability to further penetrate the molecular diagnostics market," BioFire CEO Kirk Ririe said in a statement.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.